(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 December 2009 (10.12.2009)

PCT

(10) International Publication Number
WO 2009/149171 A4

(51) International Patent Classification:
A61K 38/18 (2006.01) *C07K 14/50* (2006.01)

(21) International Application Number:
PCT/US2009/046113

(22) International Filing Date:
3 June 2009 (03.06.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/058,861	4 June 2008 (04.06.2008)	US
61/058,919	4 June 2008 (04.06.2008)	US
61/164,364	27 March 2009 (27.03.2009)	US
61/175,736	5 May 2009 (05.05.2009)	US

(71) Applicant *(for all designated States except US)*: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BELOUSKI, Edward, John** [US/US]; 4541 La Tuna Court, Camarillo, CA 93012 (US). **ELLISON, Murielle, Marie** [US/US]; 645 Camino Manzanas, Thousand Oaks, CA 91360 (US). **HAMBURGER, Agnes, Eva** [US/US]; 172 Donegal Avenue, Newbury Park, CA 91320 (US). **HECHT, Randy, Ira** [US/US]; 2569 Piccadilly, Thousand Oaks, CA 91362 (US). **LI, Yue-Sheng** [US/US]; 3025 Shadow Hill Circle, Thousand Oaks, CA 91360 (US). **MICHAELS, Mark, Leo** [US/US]; 5007 Texhoma Avenue, Encino, CA 91316 (US). **SUN, Jeonghoon** [KR/US]; 4340 Camino De La Rosa, Thousand Oaks, CA 91320 (US). **XU, Jing** [CN/US]; 1677 Glider Court, Thousand Oaks, CA 91320 (US).

(74) Agent: **LAMERDIN, John, A.**; Amgen Inc., One Amgen Center Drive, Patent Operations, M/S 28-2-C, Thousand Oaks, CA 91320-1799 (US).

[Continued on next page]

(54) Title: FGF21 MUTANTS AND USES THEREOF

(57) Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

FIG. 1A





FIG. 1B



WO 2009/149171 A4

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report: 11 March 2010

Date of publication of the amended claims: 6 May 2010